Hot Features
프리미엄
Facet Biotech (MM) (FACT)
NASDAQ
브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
PDL BioPharma Clarifies $13.00 Cost Basis in Facet Biotech Corporation PR Newswire INCLINE VILLAGE, Nev., March 24 INCLINE VILLAGE, Nev., March 24 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc...
Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Facet Biotech Corporation (NASDAQ: FACT...
Kendall Law Group, a national securities litigation firm is investigating Facet Biotech Corporation (NASDAQ: FACT) for shareholders in connection to the proposed sale of the...
Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of Facet Biotech Corporation (“Facet Biotech” or the “Company”...
Levi & Korsinsky is investigating the Board of Directors of Facet Biotech Corporation (“Facet Biotech” or the “Company”) (NasdaqGM: FACT) for possible breaches of fiduciary duty...
ABBOTT PARK, Ill. and REDWOOD CITY, Calif., March 9 /PRNewswire-FirstCall/ -- Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing...
SAN FRANCISCO, Jan. 11 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage cancer biotherapeutics company, today announced the appointment of Hoyoung Huh...
SEATTLE and REDWOOD CITY, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) and Facet Biotech Corp. (NASDAQ:FACT) today announced the presentation of positive...
Facet Biotech Corporation (Nasdaq: FACT) and Bristol-Myers Squibb Company (NYSE: BMY) announced that potentially promising data from a Phase I/II study of elotuzumab, an...
Biogen Idec Inc. (NASDAQ:BIIB) announced today that FBC Acquisition Corp., its wholly owned subsidiary, has commenced a tender offer to acquire all of the outstanding shares of...
| 기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
